Autolysosomal enhancer GHF201 attenuates pathophysiology in a mucopolysaccharidosis type I mouse model
Life Science Alliance · 2026
DOI: 10.26508/lsa.202603750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2026. Verfasst von Pradeep Kumar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel kumar.pradeep@…. Hauptthemen laut MEDLINE: Lysosomes, Mucopolysaccharidosis I. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penn | Penn Med | Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania.
Abstract (Originalsprache)
Mucopolysaccharidosis type I (MPS-I) is a hereditary lysosomal storage disorder caused by deficiency in the lysosomal enzyme α-L-iduronidase (IDUA) leading to pathogenic over-accumulation of glycosaminoglycans (GAGs), major constituent of connective tissue and mediators of cell signaling. We tested the therapeutic efficacy of the autolysosomal activator GHF201 in the Idua −/− mouse model of MPS-I. We show that GHF201 reduced GAGs and increased cathepsin activity in Idua −/− mouse embryonic fibroblasts (MEFs) and brain cells. In vivo GHF201 improved aberrant locomotion and behavior, reduced interstitial cathepsins in joints and liver, increased systemic catabolism, corrected bone dysplasia, increased autophagic flux, and ameliorated CNS neurodegeneration and neuroinflammation. GHF201 also reduced brain N-glycans, which are degraded in lysosomes. In conclusion, the lysosomal and autophagic activator GHF201 was demonstrated to improve various pathophysiological parameters in MPS-I–modeling Idua −/− female mice. Our results suggest that GHF201 can complement the inadequate Aldurazyme enzyme replacement therapy as an add-on therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel kumar.pradeep@mail.huji.ac.il.
- Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel.
- The Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, USA.
- Center for Advanced Spatial Biomolecule Research, University of Florida, Gainesville, FL, USA.
- Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
ORCID-Profile: Pradeep Kumar, Emmanuelle Merquiol, Pankaj K Singh, Roberto A Ribas, Uri Sprecher, Noam Muchtar, Miguel Weil, Or Kakhlon
Förderung
- Penn | Penn Med | Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
Zitieren
APA
Kumar, P., Merquiol, E., Avraham, T., Sinai-Turyanski, R., Singh, P. K., Ribas, R. A., Sweetat, S., Sprecher, U., Muchtar, N., Gupta, M., Mishra, K., Ojha, S. K., Yekhtin, Z., Glickstein, H., Shalev, O., Eliassaf, A., Morshina, A., Segev-Yekutiel, H., Garti, S., …, & Kakhlon, O. (2026). Autolysosomal enhancer GHF201 attenuates pathophysiology in a mucopolysaccharidosis type I mouse model. Life Science Alliance. https://doi.org/10.26508/lsa.202603750
Vancouver
Kumar P, Merquiol E, Avraham T, Sinai-Turyanski R, Singh PK, Ribas RA, et al. Autolysosomal enhancer GHF201 attenuates pathophysiology in a mucopolysaccharidosis type I mouse model. Life Science Alliance. 2026. doi:10.26508/lsa.202603750
BibTeX
@article{Kumar2026,
author = {Kumar, Pradeep and Merquiol, Emmanuelle and Avraham, Talya and Sinai-Turyanski, Reut and Singh, Pankaj K and Ribas, Roberto A and Sweetat, Sahar and Sprecher, Uri and Muchtar, Noam and Gupta, Manjeet and Mishra, Kumudesh and Ojha, Shashank Kumar and Yekhtin, Zhanna and Glickstein, Hava and Shalev, Ori and Eliassaf, Alexandra and Morshina, Anna and Segev-Yekutiel, Hadas and Garti, Sharon and Garti, Nissim and Rosenmann, Hannah and Weil, Miguel and Gentry, Matthew S and Blum, Galia and Kakhlon, Or},
title = {Autolysosomal enhancer GHF201 attenuates pathophysiology in a mucopolysaccharidosis type I mouse model},
journal = {Life Science Alliance},
year = {2026},
doi = {10.26508/lsa.202603750}
}
EUVIMED